Global Osteoarthritis Therapeutics Market Share, Size, Future Outlook, COVID-19 Impact, Forecast 2021-2027

1. Orion Market Research Global Osteoarthritis Therapeutics Market Share, Size, Future Outlook, COVID-19 Impact, Forecast 2021-2027 Request a Free Sample of our Report on Osteoarthritis Therapeutics Market: https://www.omrglobal.com/request-sample/osteoarthritis-therapeutics-market Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +91 780-304-0404

2. The global osteoarthritis therapeutics market is estimated to grow at a CAGR of 8.2% during the forecast period. Pipeline products are expected to offer an opportunity for the growth of the market. For instance, in April 2019, Pfizer Inc. and Eli Lilly and Co. declared a Phase III study outcomes assessing tanezumab 2.5 mg and 5 mg. This study was intended to compare the 16- week efficacy of tanezumab and long-term joint safety relative to nonsteroidal anti-inflammatory drugs (NSAIDs) among patients with moderate-to-severe osteoarthritis of the knee or hip. 5 mg treatment arm of the tanezumab met two from the three co-primary endpoints related to efficacy, showing a statistically potential improvement in physical function and pain than NSAIDs at the 16-week analysis. (Get 15% Discount on Buying this Report) Get Report Sample Copy @ https://www.omrglobal.com/request-sample/osteoarthritis- therapeutics-market However, patients who received 2.5 mg tanezumab did not experience a statistically potential improvement in physical function, pain, or overall assessment of patients for their osteoarthritis at 16 weeks than NSAIDs. Under the analysis for safety, there was a potential rate of events regarding joint safety in the tanezumab arms than NSAIDs at 80 weeks. As a monoclonal antibody, Tanezumab is part of an investigational drug class of non-opioid chronic pain medications referred to as nerve growth factor (NGF) inhibitors. These kinds of pipeline products with increased safety and efficacy are expected to offer an opportunity for the launch of new therapies in the future, which in turn, will likely drive the market growth. A Full Report of Global Osteoarthritis Therapeutics Market is Available at: https://www.omrglobal.com/industry-reports/osteoarthritis-therapeutics-market Scope of the Global Osteoarthritis Therapeutics Market Market Coverage •Market number available for 2019-2026 •Base year- 2019 •Forecast period- 2020-2026 •Segment Covered- By Anatomy and Drug Type •Regions Covered- North America, Europe, Asia-Pacific, and Rest of the World •Competitive Landscape- Pfizer Inc., Bayer AG, Zimmer Biomet Holdings, Inc., Sanofi S.A., and GlaxoSmithKline plc Global Osteoarthritis Therapeutics Market-Segmentation By Anatomy •Knee

3. •Ankle •Hip •Hand •Spine By Drug Type •Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) •Viscosupplementation Agents •Corticosteroids •Analgesics Global Osteoarthritis Therapeutics Market– Segment by Region North America •United States •Canada Europe •UK •Germany •Italy •Spain •France •Rest of Europe Asia-Pacific •China •India •Japan •South Korea •Rest of Asia-Pacific Rest of the World Reasons to Buying From us – 1. We cover more than 15 major industries, further segmented into more than 90 sectors. 2. More than 120 countries are for analysis. 3. Over 100+ paid data sources mined for investigation.

4. 4. Our expert research analysts answer all your questions before and after purchasing your report. For https://www.omrglobal.com/report-customization/osteoarthritis-therapeutics-market More Customized Data, Request for Report Customization @ About Orion Market Research Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. Media Contact: Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: anurag@omrglobal.com Contact no: +91 780-304-0404